TAFINLAR + MEKINIST Drug Insight and Market Forecast - 2032

This “TAFINLAR + MEKINIST Drug Insight and Market Forecast - 2032” report provides comprehensive insights about TAFINLAR + MEKINIST for glioblastoma multiforme (GBM) in the seven major markets. A detailed picture of the TAFINLAR + MEKINIST for GBM in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the TAFINLAR + MEKINIST for GBM. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the TAFINLAR + MEKINIST market forecast analysis for GBM in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in GBM.

Drug Summary

TAFINLAR (dabrafenib) + MEKINIST (trametinib) is an oral combination therapy. TAFINLAR and MEKINIST target two distinct points on the MAPK pathway studied extensively as monotherapies and in combination. TAFINLAR (dabrafenib) capsules inhibit cell growth of various BRAF V600E mutation-positive tumors in vitro and in vivo, and inhibition of MEK1 and MEK2 with MEKINIST (trametinib) tablets can suppress downstream signaling of the MAPK pathway. Alterations in the MAP-kinase pathway can inhibit normal, nontumor cells and result in side effects, some of which may be serious. Dabrafenib and Trametinib are kinase inhibitors of the BRAF and MEK1/2 proteins, respectively, approved in combination in the US, Europe, and other countries to treat patients who have certain types of cancer with a change in the BRAF gene (called a BRAF V600 mutation), including:

• Adults with unresectable or metastatic melanoma with a BRAF V600 mutation. Melanoma is a form of skin cancer; unresectable melanoma cannot be removed with surgery, and metastatic melanoma has spread to other body parts. Tafinlar and Mekinist are also approved as single agents for this indication
• Adults with stage III melanoma with a BRAF V600 mutation as an adjuvant treatment (following surgery)
• Adults with advanced non-small cell lung cancer (NSCLC) with a BRAF V600 mutation. NSCLC is the most common type of lung cancer
• Adults with locally advanced or metastatic anaplastic thyroid cancer with a BRAF V600 mutation and no satisfactory treatment options. Anaplastic thyroid cancer is a rare and aggressive form of thyroid cancer (Novartis, 2021)

The BRAF V600E mutation is estimated to be prevalent in 5-15% of all low-grade gliomas (15-20% of pediatric low-grade gliomas), including 60-80% of pleomorphic xanthoastrocytomas (PXA), 20-70% of gangliogliomas, and 10% of pilocytic astrocytomas. The mutation has been identified less frequently in high-grade gliomas, including approximately 3% of glioblastomas.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the TAFINLAR + MEKINIST description, mechanism of action, dosage and administration, research and development activities in glioblastoma multiforme (GBM).
• Elaborated details on TAFINLAR + MEKINIST regulatory milestones and other development activities have been provided in this report.
• The report also highlights the TAFINLAR + MEKINIST research and development activities in GBM across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around TAFINLAR + MEKINIST.
• The report contains forecasted sales of TAFINLAR + MEKINIST for GBM till 2032.
• Comprehensive coverage of the late-stage emerging therapies for GBM.
• The report also features the SWOT analysis with analyst views for TAFINLAR + MEKINIST in GBM.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

TAFINLAR + MEKINIST Analytical Perspective

In-depth TAFINLAR + MEKINIST Market Assessment

This report provides a detailed market assessment of TAFINLAR + MEKINIST for glioblastoma multiforme (GBM) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

TAFINLAR + MEKINIST Clinical Assessment

The report provides the clinical trials information of TAFINLAR + MEKINIST for GBM covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for glioblastoma multiforme (GBM) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence TAFINLAR + MEKINIST dominance.
• Other emerging products for GBM are expected to give tough market competition to TAFINLAR + MEKINIST and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of TAFINLAR + MEKINIST in GBM.
• This in-depth analysis of the forecasted sales data of TAFINLAR + MEKINIST from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the TAFINLAR + MEKINIST in GBM.

Key Questions

• What is the product type, route of administration and mechanism of action of TAFINLAR + MEKINIST?
• What is the clinical trial status of the study related to TAFINLAR + MEKINIST in glioblastoma multiforme (GBM) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the TAFINLAR + MEKINIST development?
• What are the key designations that have been granted to TAFINLAR + MEKINIST for GBM?
• What is the forecasted market scenario of TAFINLAR + MEKINIST for GBM?
• What are the forecasted sales of TAFINLAR + MEKINIST in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to TAFINLAR + MEKINIST for GBM?
• Which are the late-stage emerging therapies under development for the treatment of GBM?

This product will be delivered within 2 business days.